Skrebinska Sabine, Daugule Ilva, Santare Daiga, Isajevs Sergejs, Liepniece-Karele Inta, Rudzite Dace, Kikuste Ilze, Vanags Aigars, Tolmanis Ivars, Atstupens Juris, Park Jin Young, Herrero Rolando, Leja Marcis
a Institute of Clinical and Preventive Medicine, University of Latvia , Riga , Latvia.
b Faculty of Continuing Education , Riga Stradins University , Riga , Latvia.
Scand J Gastroenterol. 2018 Jun-Jul;53(7):777-783. doi: 10.1080/00365521.2018.1476909. Epub 2018 Jun 11.
The aim of the study was to assess the accuracy of two plasma Helicobacter pylori (H. pylori) antibody test-systems and a stool antigen test (SAT) system in a general population sample in Latvia.
Blood and faecal samples were analysed in healthy individuals (40-64 years), referred for upper gastrointestinal endoscopy according to pilot study protocol within a population-based study investigating gastric cancer prevention strategies (GISTAR pilot study). Antibodies to H. pylori were assessed in plasma by latex-agglutination test and enzyme-linked immunosorbent assay (ELISA). H. pylori antigen in faecal samples was detected by a monoclonal enzyme immunoassay-based SAT. Histological assessment of H. pylori based on a modified Giemsa staining method was used as the gold standard. Individuals having received H. pylori eradication within one year prior to enrolment were excluded. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and overall accuracy were calculated. Receiver-operating characteristic curves were designed to estimate the optimal diagnostic cut-off value of tests.
The analysis included 779 participants for latex-agglutination test, 1002 for ELISA and 672 individual samples for SAT. The sensitivity, specificity, PPV, NPV and overall accuracy were as follows: latex-agglutination test (86;81;87;80;84%), ELISA (97;72;83;94;86%) and SAT (87;81;87;81;85%), respectively. The optimal diagnostic cut-off value for ELISA test was ≥50.26 g/L.
Although the performance of the three tests was comparable to each other, the three test systems showed suboptimal accuracy, with important implications for public health programs based on 'test-and-treat' strategy.
本研究旨在评估两种血浆幽门螺杆菌(H. pylori)抗体检测系统和一种粪便抗原检测(SAT)系统在拉脱维亚普通人群样本中的准确性。
在一项基于人群的胃癌预防策略研究(GISTAR试点研究)中,按照试点研究方案,对因上消化道内镜检查而转诊的健康个体(40 - 64岁)的血液和粪便样本进行分析。通过乳胶凝集试验和酶联免疫吸附测定(ELISA)评估血浆中幽门螺杆菌抗体。采用基于单克隆酶免疫测定的SAT检测粪便样本中的幽门螺杆菌抗原。基于改良吉姆萨染色法的幽门螺杆菌组织学评估用作金标准。排除在入组前一年内接受过幽门螺杆菌根除治疗的个体。计算敏感性、特异性、阳性预测值(PPV)、阴性预测值(NPV)和总体准确性。设计受试者操作特征曲线以估计检测的最佳诊断临界值。
乳胶凝集试验分析了779名参与者,ELISA分析了1002名参与者,SAT分析了672个个体样本。敏感性、特异性、PPV、NPV和总体准确性分别如下:乳胶凝集试验(86;81;87;80;84%),ELISA(97;72;83;94;86%)和SAT(87;81;87;81;85%)。ELISA检测的最佳诊断临界值为≥50.26 g/L。
尽管这三种检测的性能彼此相当,但这三种检测系统的准确性欠佳,对基于“检测即治疗”策略的公共卫生项目具有重要影响。